Are SYK insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SYK leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Stock Ratings / Health Care / SYK / insiders

MMM (63) BSX (62) BDX (67) MDLN (45) ⌘ Pro Terminal →

Stryker Corporation (SYK) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$306.81 +5.12% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $309.05

Stryker Corporation (SYK) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $111.95B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SYK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SYK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Stryker Corporation (NYSE: SYK) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $306.81 (+5.12% 1D, market cap $111.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 14/20. Across 1015 tracked Health Care issuers, SYK ranks #121 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SYK compare to MMM and BSX in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), SYK carries a Roarable C (64/100 RQD), trailing P/E of 36.8x, gross margin of 64.0%, and ROIC of 11.6%. By comparison, MMM (3M Company) holds a C grade (63/100 RQD, P/E 28.2x, ROIC 32.9%, cap $90.09B) and BSX (Boston Scientific Corporation) posts a C grade (62/100 RQD, P/E 22.0x, ROIC 9.2%, cap $60.84B). Among the 5-stock peer group, BSX leads on earnings multiple (22.0x) while MMM leads on capital efficiency (32.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SYK?

▼

Per SYK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000310764), Stryker Corporation generated $25.12B in revenue (+11.2% YoY), $3.25B in net income, and $4.28B in free cash flow against $47.84B in total assets and $14.86B in total debt. Key quantitative strengths: Strong cash generator (64.0% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $309.05 (+0.73%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 17.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SYK)Realized 20D OHLCV Swing Band: ±6.4%

Deterministic 5-Pillar Attribution (64/100 Composite)

🔍 WHY SYK SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 17.1% FCF Margin ($4.28B FCF) & 64% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 4.46 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)

Macro rate sensitivity & RSI-14 (47.3) create a -12 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$281.62+5.7% Next Q

Q2 (-2Q)

Grade C$297.60+2.2% Next Q

Q3 (-1Q)

Grade C$304.00+0.9% Next Q

Current

Grade C$306.81+1.1% Hist 90D α

Trajectory: C (56) → C (64)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SYK Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, SYK faces multiple-compression risk if 36.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 61.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($291.26) or 200D SMA ($322.97) invalidates the momentum regime and cuts Target Base ($315.09) toward Bear Floor ($245.77).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SYK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SYK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 64%NO 36%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SYK Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SYK)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SYK. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (SYK Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SYK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.48%⚡ TESTING RESISTANCE

2026-11-03O $311.8H $311.8L $291.9C $306.8VOL 6.44M

RES: $310.4SUP: $254.0SMA50: $291.3SMA200: $323.0

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SYK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SYK Butterfly Map → + Track SYK →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

28.3%/yr Implied 5Y Growth

vs. +11.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SYK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SYK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SYK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SYK)

Health Care Rank #121 of 1015 ⚔️ MMM vs SYK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SYK vs. MMM, BSX, BDX, MDLN)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Stryker Corporation (SYK) ranks #121 by composite RQD confidence (64/100, grade C) and #20 by equity capitalization ($111.95B). Within this direct 5-issuer industry benchmark cohort, BSX leads on earnings valuation at 22.0x trailing P/E, while MMM leads on capital efficiency and profitability with 32.9% ROIC and 39.9% gross margin. BDX currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with SYK at 64/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SYK ACTIVE Stryker Corporation	C	64/100	36.8x	64.0%	11.6%	+5.12%	$111.95B	Benchmark Subject
MMM 3M Company	C	63/100	28.2x	39.9%	32.9%	+2.31%	$90.09B	/mmm-vs-syk →
BSX Boston Scientific Corporation	C	62/100	22.0x	69.0%	9.2%	+5.57%	$60.84B	/bsx-vs-syk →
BDX Becton Dickinson and Company	C+	67/100	32.2x	45.4%	4.9%	+0.36%	$53.90B	/bdx-vs-syk →
MDLN Medline Inc.	D	45/100	—	—	8.2%	+4.70%	$42.23B	/mdln-vs-syk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000310764 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Stryker Corporation (SYK) reported GAAP revenue of $25.12B (+11.2% vs. FY2024 revenue of $22.59B , and +22.5% cumulative change since FY2023) , GAAP net income of $3.25B, operating cash flow of $5.04B, and free cash flow of $4.28B (+22.8% YoY). On the balance sheet, SYK closed FY2025 with $47.84B in total assets against $14.86B in total debt (Altman Z-Score: 4.46, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$25.12B	$3.25B	$5.04B	$4.28B	$47.84B	$14.86B
FY2024 (FY)	2024-12-31	$22.59B	$2.99B	$4.24B	$3.49B	$42.97B	$12.19B
FY2023 (FY)	2023-12-31	$20.50B	$3.17B	$3.71B	$2.79B	$65.77B	$15.39B

3. SYK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SYK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SYK compare to MMM and BSX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SYK?

Where is SYK trading relative to its 50-day, 200-day, and 52-week technical levels?

SYK last traded at $306.81 (+5.12% on volume of 3,741,507 shares), positioning the stock +5.34% above its 50-day simple moving average ($291.26) and -5.00% below its 200-day simple moving average ($322.97). Across its 52-week range of $267.00 to $389.33, SYK sits at the 32.5% percentile with a 14-day RSI of 47.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.4% ($287.17 to $326.45).

Direct Sub-Reports: SYK RQD Cockpit SYK 12M Forecast SYK Earnings & Move SYK Dividends & DRIP SYK Insiders & 13F SYK Whale Options SYK Profit Sankey SYK News & Why

ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ SEC XBRL & RQD VERIFIED

SYK — Stryker Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Stryker Corporation (SYK) earns a live Roarable RQD composite score of 64/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $306.81 (+5.12% 1D, market capitalization $111.95B).

Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 11.6%, gross margin of 64.0%, operating margin of 19.5%, and free cash flow yield of 3.58%.
Whale 13F & Options Flow (10/20) + Insider Conviction (14/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (16/20): Incorporates a 1.13x equity beta, Altman Z-Score of 4.46, Piotroski F-Score of 9/9, and Debt/Equity of 0.66x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Stryker Corporation is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. — for product lines, customer segments, or revenue model detail. The company's scale is reflected in its market capitalization of $119.6B and reported FY 2025 revenue of $25.12B .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Stryker Corporation (SYK) reported $25.12B in annual revenue (up from $22.59B in FY2024, +11.2% YoY) and $3.25B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($20.50B revenue, $3.17B net income) through FY2025, SYK scaled operating cash flow to $5.04B and free cash flow to $4.28B, backed by $47.84B in total assets against $14.86B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C • RQD 64/100): Strong cash generator (64.0% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $267.00 – $389.33 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 36.8x trailing P/E and 23.6x EV/EBITDA against 19.5% operating margins and a 1.13x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph contains no upstream or downstream links, no sector correlations, and no proprietary signals for SYK. The only sector-level context available is the Health Care classification and the Benzinga-reported Q3 earnings miss referenced in the news wire, which is not linked to any named supplier or customer in the sources.

Key Question #1: Can SYK sustain or expand its 19.5% operating margin and 11.6% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $25.12B and free cash flow of $4.28B, how will capital allocation balance growth reinvestment against $14.86B in total debt?
Key Question #3: How sensitive is SYK's 34.2x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.13x)?

SYK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Stryker Corporation (SYK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SYK Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 1d ago

Is Stryker Corp. (SYK) Positioned for Above-Market Growth?

Yahoo Finance report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Stryker Corp Stock (SYK) Moved Up by 3.32% on Oct 5: Facts Behind the Movement

TradingKey report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 1d ago

Stryker: This Dividend Aristocrat Is Finally Cheap Again (NYSE:SYK)

Seeking Alpha report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Stryker Stock Price Forecast. Should You Buy SYK?

StockInvest.us report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy?

Yahoo Finance report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Benzinga • 1d ago

Stryker Shares Fall 11.8% After Hours After Q3 Earnings Miss - Stryker (NYSE:SYK)

Benzinga report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH GuruFocus • 1d ago

Stryker Corporation (SYK) Shares Drop 13% After Q3 Earnings Miss and Lowered Guidance

GuruFocus report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Stryker (SYK): Near-Term Growth Concerns Overshadow Long-Term Strength

Yahoo Finance report covering Stryker Corporation (SYK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SYK Bull vs. Bear Conversation Board — What's Your Call at $306.81?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SYK 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $338.56 (+16.0%)

📌 Pinned Debate

Cash generation and forensic balance-sheet pillars (16/20 each, Piotroski F 9/9) support financial quality.

Picked up a starter position in SYK in my $100K Virtual Cash book at $291.86. Cash generation and forensic balance-sheet pillars (16/20 each, Piotroski F 9/9) support financial quality.. Trading inside a $267.00–$389.33 52-week range with 3.58% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

CapAlloc_Nerd 🐂 BULL

@CashFlowKing Agree on the RQD 64/100 quality, though with 1.13 beta I'm scaling in with half-size at $291.86 and keeping dry powder in case we test $271.43.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $218.90 (-25.0%)

Spot @ $291.86

Premium valuation (P/E TTM 36.8, EV/EBITDA 23.6) with a 3.58% FCF yield leaves limited margin of safety after a Q3 earnings miss.

Careful chasing SYK at $291.86. Premium valuation (P/E TTM 36.8, EV/EBITDA 23.6) with a 3.58% FCF yield leaves limited margin of safety after a Q3 earnings miss.. Gross margin is 64.0%, but operating margin is 19.5%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $218.90 on multiple compression.